SCHEMBL3168312

SCHEMBL3168312

CC(C)C[C@H](NC(=O)[C@H](CCCNC(=N)N[N+](=O)[O-])NC(=O)CN)B1O[C@@H]2C[C@@H]3C[C@@H](C3(C)C)[C@]2(C)O1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 19/20 0.55
PSMB1 P20618 11/20 0.55
PSMB2 P49721 10/20 0.55
PSMB11 A5LHX3 9/20 0.55
PSMD11 O00231 9/20 0.55
PSMD12 O00232 9/20 0.55
PSMD14 O00487 9/20 0.55
PSMA7 O14818 9/20 0.55
PSMD3 O43242 9/20 0.55
PSMC3 P17980 9/20 0.55
PSMA1 P25786 9/20 0.55
PSMA2 P25787 9/20 0.55
PSMA3 P25788 9/20 0.55
PSMA4 P25789 9/20 0.55
PSMB8 P28062 9/20 0.55
PSMB9 P28065 9/20 0.55
PSMA5 P28066 9/20 0.55
PSMB4 P28070 9/20 0.55
PSMB6 P28072 9/20 0.55
PSMC2 P35998 9/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3173472 0.95 PSMB5 (0.54) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL1477637 0.94 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL10243593 0.94 PSMB5 (0.56) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL606363 0.93 PSMB5 (0.52) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL1478345 0.93 PSMB5 (0.54) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL609141 0.93 PSMB5 (0.62) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL1478145 0.93 PSMB5 (0.52) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL607190 0.93 PSMB5 (0.52) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL608650 0.92 PSMB5 (0.55) PSMB5PSMB1PSMB2PSMB11PSMD11
SCHEMBL609290 0.92 PSMB5 (0.57) PSMB5PSMB1PSMB2PSMB11PSMD11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 EP claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 US disclosed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 US disclosed
US-7576206-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2009-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 PSMB5 2/4885PSMB1 4/4885PSMB2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.